Athlete A | Athlete B | Athlete C* | Athlete D | |
Age | 27 | 21 | 21 | 18 |
Sex | Male | Male | Male | Male |
SARS-CoV-2 symptoms | Cough | Fever and cough | Nasal congestion, muscle ache and tiredness | Nasal congestion, headache, loss of smell and taste |
Cardiac symptoms | None | None | Palpitations | None |
Post-infection ECG abnormalities | None | None | Decrease of T wave amplitude in lead II and aVF, and T-wave inversion in lead III | New inferolateral T wave inversions |
Infection to assessment interval | 5 months | 5 months | 1 month | 10 days |
Initial cardiac MRI | ||||
LGE | Basal to apical lateral myocardial and pericardial | Focal pericardial/epicardial at inferolateral midventricular wall with pericardial effusion (PE) | Basolateral to midventricular posterior epicardial | Pericardial/epicardial LGE at the inferolateral wall |
Native T1 relaxation time (ms) | 939±63 ms | NA | 1232±101 ms | NA |
Sports restriction | No | No | 9 months | 1 month |
LGE evolution | Complete resolution (8 and 18 months) | Persisting LGE without PE (10 and 17 months) | Persisting LGE without inflammation (15 months) | Persisting LGE (3 and 9 months) |
Return to sports | No active myocardial inflammation | No active myocardial inflammation | After resolution of symptoms, ECG abnormalities, myocardial inflammation (assessed by PET-CT) and normalisation of cardiac biomarkers | After resolution of symptoms and ECG abnormalities and in the absence of elevated inflammatory markers |
*The clinical course of this case, including LGE evolution, has been extensively described elsewhere.24
aVF, augmented vector foot; LGE, late gadolinium enhancement.